Filing Details
- Accession Number:
- 0001209191-22-031844
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-05-25 16:05:40
- Reporting Period:
- 2022-05-23
- Accepted Time:
- 2022-05-25 16:05:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1446847 | Ironwood Pharmaceuticals Inc | IRWD | Pharmaceutical Preparations (2834) | 043404176 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1478448 | A Thomas Mccourt | C/O Ironwood Pharmaceuticals, Inc. 100 Summer Street, Suite 2300 Boston MA 02110 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Disposition | 2022-05-23 | 2,587 | $11.50 | 832,602 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2022-05-23 | 21,873 | $11.50 | 810,729 | No | 4 | S | Direct | |
| Class A Common Stock | Disposition | 2022-05-23 | 11,848 | $11.50 | 798,881 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on May 1, 2019.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 50% of the reporting person's restricted stock units granted on March 26, 2021.
- This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on June 7, 2021.
Billionaire Hedge Funds
